What does this video actually claim?
Without access to the specific video content, we can infer from Dr. Noor Al-Humaidhi's hashtags and category that this Instagram post discusses testosterone therapy for women during perimenopause and menopause. The post appears to be part of broader hormone replacement therapy (HRT) education content.
Based on the TRT categorization and women's health focus, the video likely addresses testosterone supplementation as part of menopausal hormone therapy. This represents a growing area of clinical interest, though one where evidence remains more limited than for estrogen-based HRT.
Does the science support testosterone for menopausal women?
The research shows modest benefits for specific symptoms, but it's not the hormone therapy game-changer some claim. The largest randomized trial, the INTIMATE study (Davis et al., NEJM, 2019), found that 300 micrograms daily of transdermal testosterone improved sexual function scores by 1.31 points on a 28-point scale compared to placebo in postmenopausal women already on estrogen therapy.
That's statistically significant but clinically modest. The Global Consensus Position Statement (Davis et al., Climacteric, 2019) concluded that testosterone therapy can be considered for postmenopausal women with hypoactive sexual desire disorder who are already receiving estrogen therapy.
However, data on other claimed benefits like energy, mood, and cognitive function remains weak. Most studies focus on sexual function because that's where the clearest signal exists.
What are the actual risks and limitations?
The safety data is reassuring but limited to short-term studies. The INTIMATE trial showed no increase in cardiovascular events, breast cancer, or other serious adverse effects over 52 weeks, but we don't have long-term safety data comparable to what exists for estrogen therapy.
Common side effects include acne, hair growth, and voice changes, which occurred in about 5-10% of women in clinical trials. These androgenic effects are dose-dependent and often irreversible, particularly voice deepening.
The bigger issue is that most testosterone products aren't FDA-approved for women. Clinicians typically prescribe male formulations at much lower doses, creating dosing challenges and potential quality control issues.
What's the clinical reality for prescribing?
Most major medical societies remain cautious about routine testosterone prescribing for menopausal women. The North American Menopause Society's 2022 position statement supports considering testosterone only for postmenopausal women with low sexual desire who haven't responded to other interventions and are already on estrogen therapy.
The Endocrine Society goes further, recommending against testosterone therapy for most menopausal symptoms except in research settings. This conservative stance reflects the limited evidence base and lack of approved formulations.
In clinical practice, testosterone testing in women is notoriously unreliable. Most commercial assays can't accurately measure the low testosterone levels in women, making diagnosis of "low testosterone" problematic.
What should women actually know?
Testosterone therapy isn't a magic bullet for menopausal symptoms. The evidence supports a narrow use case: postmenopausal women with sexual desire problems who are already on estrogen therapy and haven't responded to other approaches.
If you're considering testosterone therapy, expect modest improvements at best. The INTIMATE study's 1.31-point improvement on sexual function scales translates to relatively small real-world changes for most women.
Don't expect benefits for energy, mood, or cognitive symptoms. These claims aren't supported by rigorous clinical trial data, despite their popularity on social media and in some clinical practices.